Cover: Drug Licenses

Drug Licenses

A New Model for Pharmaceutical Pricing

Published in: Health Affairs, v. 27, No. 1, Jan.-Feb. 2008, p. 122-129

by Dana P. Goldman, Anupam B. Jena, Tomas Philipson, Eric Sun

View related products

Read More

Access further information on this document at content.healthaffairs.org

This study was published in a peer-reviewed scholarly journal. The full text of the study can be found at the link above.

Abstract

High drug prices are a major barrier to patients' access to drugs and compliance with treatment. Yet low drug prices are often argued to provide inadequate incentives for innovation. We propose a drug-licensing model for health care, which has the promise of increasing drug use without altering patients' out-of-pocket spending, health plans' costs, or drug companies' profits. In such a model, people would purchase annual drug licenses that would guarantee unfettered access to a clinically optimal number of prescriptions over the course of a year. Using the example of statins, the authors illustrate how such a model could be implemented.

Research conducted by

This report is part of the RAND Corporation external publication series. Many RAND studies are published in peer-reviewed scholarly journals, as chapters in commercial books, or as documents published by other organizations.

The RAND Corporation is a nonprofit institution that helps improve policy and decisionmaking through research and analysis. RAND's publications do not necessarily reflect the opinions of its research clients and sponsors.